Replies to post #74076 on DNAprint Genomics (DNAG)

[cloud477]

Good post, Chris.

best of luck

[onebigbang]

Chrisbaskett.....fwiw... DNAPrint never answers any of my emails either, which is very annoying to me. Either they are involved in some very sensitive negotiations and must keep quiet or they have absolutely nothing of value going on. I would sincerely hope the situation relates to the former and not the latter.

Cheers

[johnnyfiber]

you're not a basher...but if you were, what would you say about this:

I'd say...DnaPrint's technology used microsatellites and SNP's to develop this test along with Bioserve. I believe that's BioserveDnaPrint LLC. A Maryland based company.

The ATP-Binding Cassette Transporter A1 R230C Variant Affects HDL Cholesterol Levels and BMI in the Mexican Population
Association With Obesity and Obesity-Related Comorbidities


The AdmixMap program was used to test the possible effect of population stratification on associations with obesity, the metabolic syndrome, and type 2 diabetes (32,33). Because the Mexican-Mestizo population derived mainly from Amerindian and European (Spanish) populations, the model used included two primary parental populations. AdmixMap fits a logistic regression model of the trait on individual admixture, and it allows the inclusion of covariates such age, sex, BMI, HDL, apoA-I, and other potential confounders. Previously reported Amerindian and European ancestral allele frequencies were used for the analysis

and plasma apoA-I and apoB were measured using a commercially available kit (Beckman).

http://diabetes.diabetesjournals.org/cgi/content/full/56/7/1881

=============================================================

BioServe Announces ControlMATCH for More Efficient Biomarker Validation
December 4, 2007
New line of DNA and serum samples for Type II diabetes, hypertension and hyperlipidemia provide researchers access to clinically defined controls to validate biomedical research results
Beltsville, MD – BioServe today introduced ControlMATCH, a new line of fully annotated control DNA and serum samples designed to help biomedical researchers efficiently validate new biomarkers and early stage clinical trial drug candidates. Leveraging BioServe's Global Repository of 600,000 human biological samples, ControlMATCH allows researchers to select and match control samples to the specific needs of their own DNA and/or serum-based studies.

ControlMATCH DNA and serum controls will initially cover type II diabetes, hypertension and hyperlipidemia, and extend to other disease states in early 2008.

ControlMATCH normal samples for type II diabetes, hypertension and hyperlipidemia are annotated with body mass index (BMI), confirmed normal blood glucose levels, confirmed normal blood pressure and cholesterol levels, and a family history of health status and ethnicity determined by data collected on three generations. ControlMATCH therefore permits researchers to identify one-to-one matched controls for extended criteria such as age, gender, ethnicity, BMI, diet and a host of lifestyle factors. Furthermore, ControlMATCH includes clinically confirmed negative results enabling researchers to further confirm that their markers are valued against the correct set of controls.

http://www.genomicsinc.com/company/articles/120407.cfm